Patent details

EP2804609 Title: TETRAHYDROFOLATES IN COMBINATION WITH EGFR-INHIBITORS

Basic Information

Publication number:
EP2804609
PCT Application Number:
EP2013050973
Type:
European Patent Granted for LU
Legal Status:
Lapsed
Application number:
EP137010401
PCT Publication Number:
WO2013107883
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
TETRAHYDROFOLATES IN COMBINATION WITH EGFR-INHIBITORS
French Title of Invention:
TÉTRAHYDROFOLATES EN COMBINAISON AVEC LES INHIBITEURS EGFR DANS L'UTILISATION POUR LE TRAITEMENT DU CANCER
German Title of Invention:
TETRAHYDROFOLATE IN KOMBINATION MIT EGFR-INHIBITOREN ZUR VERWENDUNG BEI DER KREBSBEHANDLUNG
SPC Number:

Dates

Filing date:
18/01/2013
Grant date:
13/06/2018
EP Publication Date:
26/11/2014
PCT Publication Date:
25/07/2013
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
13/06/2018
EP B1 Publication Date:
13/06/2018
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
18/01/2019
Expiration date:
18/01/2033
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
06/06/2018
 
 

Name:
Isofol Medical AB
Address:
Biotech Center Arvid Wallgrens Backe 20, 413 46 Göteborg, Sweden (SE)

Inventor

1

Name:
CARLSSON, Björn
Address:
Sweden (SE)

2

Name:
GUSTAVSSON, Bengt
Address:
Sweden (SE)

Priority

Priority Number:
12151993
Priority Date:
20/01/2012
Priority Country:
European Patent Office (EPO) (EP)

Classification

IPC classification:
A61K 31/44; A61K 31/4704; A61K 31/519; A61K 39/00; A61K 39/395; A61K 45/06; A61P 35/00; C07K 16/28;

Publication

European Patent Bulletin

Issue number:
201824
Publication date:
13/06/2018
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
31/05/2019 Outgoing Correspondence 1